Items Tagged ‘KEYNOTE-001 trial’

October 13th, 2015

FDA Approves Keytruda® for Lung Cancer

By

The programmed death (PD-1) inhibitor Keytruda® (pembrolizumab) has been granted approval by the US Food and Drug Administration (FDA) for use in lung cancer, becoming the first PD-1 inhibitor and the second immunotherapy available for treatment of this disease. PD-1 is a protein that inhibits certain types of immune responses. Drugs that block PD-1, such […]

View full entry

Tags: General Lung Cancer, KEYNOTE-001 trial, keytruda, Lung Cancer, News, PD-1 inhibitor, PD-L1, pembrolizumab